Description of Research Expertise:
Justin E. Bekelman, M.D., is Associate Professor in the Departments of Radiation Oncology and Medical Ethics and Health Policy at the Perelman School of Medicine, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Penn Center for Precision Medicine and the Leonard Davis Institute for Health Economics, all at the University of Pennsylvania. Dr. Bekelman leads research programs in cancer comparative effectiveness and delivery system and payment reform, integrating methods from the fields of epidemiology, clinical trials, health economics and public policy. In his delivery system and payment reform research, Dr. Bekelman leads a series of studies to evaluate the impact of new payment models and financial and non-financial strategies to improve the quality, outcomes and affordability of cancer treatments and reduce unnecessary variation in clinical practice. In his comparative effectiveness research, Dr. Bekelman leads the multi-institution Radiation Comparative Effectiveness Consortium (RADCOMP) pragmatic randomized clinical trial network for breast cancer, and co-leads the PARTIQoL efficacy randomized clinical trial for prostate cancer. Dr. Bekelman's research has appeared in scientific journals such as the Journal of the American Medical Association and the Journal of Clinical Oncology and has been featured in the mainstream media, including the New York Times, the Wall Street Journal, National Public Radio, and news outlets in Canada and Europe. He has received research funding from the National Cancer Institute, the Patient-Centered Outcomes Research Institute, the American Cancer Society, and philanthropic sources.
Dr. Bekelman completed his undergraduate studies at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
Yasaitis L, Polsky D*, Bekelman J*: Relation between Narrow Networks and Providers of Cancer Care Journal of Clinical Oncology : 2017.
Bekelman JE and Lee WR: 6 Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer
Int J Radiat Oncol Biol Phys 97 (4): 718-721,2017.
Ojerholm E, Halpern SD, Bekelman JE: Default options: opportunities to improve quality and value in oncology Journal of Clinical Oncology 34 (16): 1844-7,2016.
Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ: Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries JAMA 315 (3): 272-283,2016.
Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K: Effectiveness of Androgen Deprivation Therapy and Radiotherapy for Older Men with Locally Advanced Prostate Cancer Journal of Clinical Oncology 33 (7): 716-22,2015.
Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Uzzo RG, Small DS, Mitra N, Bekelman JE: Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer JAMA Oncology 1 (7): 897-906,2015.
Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ: Uptake and Costs of Hypofractionated vs. Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008 - 2013 JAMA 312 (23): 2542-50,2014.
Bekelman JE, Kim M, Emanuel EJ: Toward Accountable Cancer Care JAMA Internal Medicine 173 (11): 958-9,2013.
Bekelman JE, Epstein AJ, Emanuel EJ: Single vs Multiple Fraction Radiotherapy for Bone Metastases from Prostate Cancer JAMA 310 (14): 1501-02,2013.
View all publications